Skip to main content
Erschienen in: Journal of Cancer Survivorship 1/2020

04.11.2019

Implementation of the Smoking Treatment and Recovery (STAR) program: healthy cancer survivorship through integrated tobacco control

verfasst von: Kathryn L. Taylor, Shelby Fallon, Deepa Subramaniam, Kimberly Davis, Chan To, Tania Lobo, Kenneth P. Tercyak, Julia Friberg, Mara Tynan, Emily Russell, Waseem Ahmed, Mary Chris Ponder, Lisa Cusaac, Jillian Thompson, Kellie Gardner, Chul Kim, Louis M. Weiner

Erschienen in: Journal of Cancer Survivorship | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

It is well-established that persistent tobacco use among patients with cancer results in numerous adverse outcomes. However, the assessment and treatment of tobacco use with evidence-based methods have been lacking in cancer care. Our cancer center has established its first tobacco treatment program, a multidisciplinary, evidence-based, clinical program for hematology/oncology patients.

Methods

We describe the development and implementation of the program, emphasizing lessons learned in treating nicotine addiction among patients who are at very high risk for continuing to use tobacco throughout the survivorship phase.

Results

We developed a system to assess tobacco use at each outpatient visit, from those recently diagnosed to long-term survivors. For patients who have smoked in the past month, the protocol offers standard behavioral and pharmacological treatments, delivered by tobacco treatment specialists and nurse practitioners over four in-person and/or telephone-based sessions. Partnerships with the Psychosocial Oncology and Cancer Survivorship Programs have provided integrated and comprehensive care for patients during and after their cancer treatment.

Conclusions

The systematic efforts to reach and engage current smokers have laid the groundwork for maximizing the program’s future effectiveness and impact. Our initial results demonstrate not only the complexities but also the feasibility of developing a new tobacco treatment program in the oncology setting.

Implications for cancer survivors

The implications for cancer survivors are the significant improvements in treatment outcomes that occur with tobacco abstinence.
Literatur
1.
Zurück zum Zitat U.S. Department of Health and Human Services. The health consequences of smoking: 50 years of progress: a report of the surgeon general. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014. U.S. Department of Health and Human Services. The health consequences of smoking: 50 years of progress: a report of the surgeon general. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
2.
Zurück zum Zitat Gallaway M, Glover-Kudon R, Momin B, Puckett M, Lunsford NB, Ragan K, et al. Smoking cessation attitudes and practices among cancer survivors- United States, 2015. J Ca Surviv. 2019;13(1):66–74.CrossRef Gallaway M, Glover-Kudon R, Momin B, Puckett M, Lunsford NB, Ragan K, et al. Smoking cessation attitudes and practices among cancer survivors- United States, 2015. J Ca Surviv. 2019;13(1):66–74.CrossRef
3.
Zurück zum Zitat Croyle RT, Morgan GD, Fiore MC. Addressing a core gap in cancer care- The NCI Moonshot program to help oncology patients stop smoking. N Engl J Med. 2019;380(6):512–5.CrossRef Croyle RT, Morgan GD, Fiore MC. Addressing a core gap in cancer care- The NCI Moonshot program to help oncology patients stop smoking. N Engl J Med. 2019;380(6):512–5.CrossRef
4.
Zurück zum Zitat Land SR, Toll BA, Moinpour CM, Mitchell SA, Ostroff JS, Hatsukami DK, et al. Research priorities, measures, and recommendations for assessment of tobacco use in clinical cancer research. Clin Cancer Res. 2016;22(8):1907–13.CrossRef Land SR, Toll BA, Moinpour CM, Mitchell SA, Ostroff JS, Hatsukami DK, et al. Research priorities, measures, and recommendations for assessment of tobacco use in clinical cancer research. Clin Cancer Res. 2016;22(8):1907–13.CrossRef
5.
Zurück zum Zitat Gaglio B, Shoup JA, Glasgow RE. The RE-AIM framework: a systematic review of use over time. Am J Public Health. 2013;103(6):e38–46.CrossRef Gaglio B, Shoup JA, Glasgow RE. The RE-AIM framework: a systematic review of use over time. Am J Public Health. 2013;103(6):e38–46.CrossRef
6.
Zurück zum Zitat Karam-Hage M, Oughli HA, Rabius V, Beneventi D, Wippold RC, Blalock JA, et al. Tobacco cessation treatment pathways for patients with cancer: 10 years in the making. J Natl Compr Cancer Netw. 2016;14(11):1469–77.CrossRef Karam-Hage M, Oughli HA, Rabius V, Beneventi D, Wippold RC, Blalock JA, et al. Tobacco cessation treatment pathways for patients with cancer: 10 years in the making. J Natl Compr Cancer Netw. 2016;14(11):1469–77.CrossRef
7.
Zurück zum Zitat Warren GW, Ward KD. Integration of tobacco cessation services into multidisciplinary lung cancer care: rationale, state of the art, and future directions. Transl Lung Cancer Res. 2015;4(4):339–52.PubMedPubMedCentral Warren GW, Ward KD. Integration of tobacco cessation services into multidisciplinary lung cancer care: rationale, state of the art, and future directions. Transl Lung Cancer Res. 2015;4(4):339–52.PubMedPubMedCentral
9.
Zurück zum Zitat Warren GW, Marshall JR, Cummings KM, Toll B, Gritz ER, Hysert P, et al. Automated tobacco assessment and cessation support for cancer patients. Cancer. 2014;120(4):562–9.CrossRef Warren GW, Marshall JR, Cummings KM, Toll B, Gritz ER, Hysert P, et al. Automated tobacco assessment and cessation support for cancer patients. Cancer. 2014;120(4):562–9.CrossRef
10.
Zurück zum Zitat Antwi GO, Lohrmann DK, Jayawardene W, Chow A, Obeng CS, Sayegh AM. Associations between e-cigarette and combustible cigarette use among U.S. cancer survivors: implications for research and practice. J Cancer Surviv. 2019;13(2):316–25.CrossRef Antwi GO, Lohrmann DK, Jayawardene W, Chow A, Obeng CS, Sayegh AM. Associations between e-cigarette and combustible cigarette use among U.S. cancer survivors: implications for research and practice. J Cancer Surviv. 2019;13(2):316–25.CrossRef
Metadaten
Titel
Implementation of the Smoking Treatment and Recovery (STAR) program: healthy cancer survivorship through integrated tobacco control
verfasst von
Kathryn L. Taylor
Shelby Fallon
Deepa Subramaniam
Kimberly Davis
Chan To
Tania Lobo
Kenneth P. Tercyak
Julia Friberg
Mara Tynan
Emily Russell
Waseem Ahmed
Mary Chris Ponder
Lisa Cusaac
Jillian Thompson
Kellie Gardner
Chul Kim
Louis M. Weiner
Publikationsdatum
04.11.2019
Verlag
Springer US
Erschienen in
Journal of Cancer Survivorship / Ausgabe 1/2020
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-019-00826-1

Weitere Artikel der Ausgabe 1/2020

Journal of Cancer Survivorship 1/2020 Zur Ausgabe

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.